NR4A3 Fusion

CI-VAR-00001226Explore in graph →CIViC 2385

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Extraskeletal Myxoid Chondrosarcoma3
EWSR1::NR4A3 Fusion	Pazopanib	Predictive	B	Supports Sensitivity Response	3	submitted	EID9819 In this single-arm, open-label phase 2 trial, extraskeletal myxoid chondrosarcoma patients treated with pazopanib were reported and 22/23 patients (one patient died before the primary analysis) were e… (full text at CIViC) PMID 31331701 · Stacchiotti et al., 2019 · Open in CIViC	civic
EWSR1::NR4A3 Fusion	Sunitinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID6378 his report confirms the therapeutic activity of sunitinib in extraskeletal myxoid chondrosarcoma. Genotype/phenotype analyses support a correlation between response and EWSR1-NR4A3 fusion. PMID 24703573 · Stacchiotti et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.